Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 09:40PM GMT
Release Date Price: $70 (+0.11%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Salveen Richter, one of the biotechnology analysts at Goldman Sachs, and we're pleased to have Alnylam with us. And with us we have Barry Greene, President of Alnylam.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

So Barry, maybe to start. Back in 2015, you announced Alnylam 2020, your initiative to kind of -- to end that year with 3 marketed products, 10 clinical programs and 4 in late stages of development across 3 verticals. So as we sit here, you've got 1.5 years to go, where are you faring on that?

Barry E. Greene
Alnylam Pharmaceuticals, Inc. - President

Yes. So first of all, thanks for having us, and appreciate Goldman for having us in this conference, incredible venue. Thank you for being here.

So yes, you're exactly right. We felt, starting actually in 2011, that it was important for Alnylam to provide multiyear guidance. We, of course, are a platform technology. We've

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot